In yesterday’s Wall Street session, Edwards Lifesciences Corporation (NYSE:EW) shares traded at $83.84, down -1.06% from the previous session.
30 analysts cover Edwards Lifesciences Corporation (NYSE:EW), according to research data. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $105.00 and a low of $73.00, we find $95.00. Given the previous closing price of $84.74, this indicates a potential upside of 12.11 percent. EW stock price is now -1.24% away from the 50-day moving average and 1.71% away from the 200-day moving average. The market capitalization of the company currently stands at $50.52B.
25-cent Stock Takes $11T Commodities Sector Digital
One brilliantly-run technology firm has successfully partnered with some of the largest players in the industry to bring a first-of-its-kind digital solution to the global commodities supply chain sector. Best of all, this upstart technology firm is currently trading undiscovered — below 25-cents per share — so very, very few investors know about it yet! For investors… it's an early-stage opportunity in a company that's bringing the US$11T global commodities sector straight into the 21st century.
All the details are in the FREE online report you can get here.
The stock has received a hold rating from 14 analysts and a buy rating from 13. Brokers who have rated the stock have averaged $94.20 as their price target over the next twelve months.
In other news, Wood Larry L, Global President TAVR & Surg sold 6,421 shares of the company’s stock on May 24. The stock was sold for $540,841 at an average price of $84.23. Upon completion of the transaction, the Global President TAVR & Surg now directly owns 213,794 shares in the company, valued at $17.92 million. An SEC document containing details of the transaction can be found on the SEC’s website. On May 10, CVP, Chief Financial Officer Ullem Scott B. sold 80,700 shares of the business’s stock. A total of $7,145,004 was realized by selling the stock at an average price of $88.54. This leaves the insider owning 18,294 shares of the company worth $1.53 million. Insiders disposed of 663,499 shares of company stock worth roughly $55.63 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in EW stock. A new stake in Edwards Lifesciences Corporation shares was purchased by SCOUT INVESTMENTS, INC. during the first quarter worth $63,266,000. PROVIDENT INVESTMENT MANAGEMENT, INC. invested $36,276,000 in shares of EW during the first quarter. In the first quarter, QUINTET PRIVATE BANK (EUROPE) S.A. acquired a new stake in Edwards Lifesciences Corporation valued at approximately $35,546,000. RMB CAPITAL MANAGEMENT, LLC acquired a new stake in EW for approximately $31,781,000. LA FINANCIERE DE L’ECHIQUIER purchased a new stake in EW valued at around $19,356,000 in the second quarter. In total, there are 1,762 active investors with 84.90% ownership of the company’s stock.
On Wednesday morning Edwards Lifesciences Corporation (NYSE: EW) stock kicked off with the opening price of $84.23. During the past 12 months, Edwards Lifesciences Corporation has had a low of $67.13 and a high of $107.92. As of last week, the company has a debt-to-equity ratio of 0.10, a current ratio of 3.00, and a quick ratio of 2.20. According to the stock market information, the enterprise value for the company is $51.99B, which is based on a 34.89 price-to-earnings ratio, a 3.57 price-to-earnings-growth ratio, and a beta of 1.01. The fifty day moving average price for EW is $85.01 and a two-hundred day moving average price translates $82.32 for the stock.
The latest earnings results from Edwards Lifesciences Corporation (NYSE: EW) was released for Mar, 2023. According to the Medical Devices Company, earnings per share came in at $0.62, beating analysts’ expectations of $0.61 by 0.01. This compares to $0.59 EPS in the same period last year. The net profit margin was 27.10% and return on equity was 24.90% for EW. The company reported revenue of $1.46 billion for the quarter, compared to $1.34 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 8.83 percent. For the current quarter, analysts expect EW to generate $1.5B in revenue.
Edwards Lifesciences Corporation(EW) Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient’s heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Leave a Reply